Literature DB >> 18426919

A viral RNA competitively inhibits the antiviral endoribonuclease domain of RNase L.

Hannah L Townsend1, Babal K Jha, Jian-Qiu Han, N Karl Maluf, Robert H Silverman, David J Barton.   

Abstract

Ribonuclease L (RNase L) is a latent endoribonuclease in an evolutionarily ancient interferon-regulated dsRNA-activated antiviral pathway. 2'-5' oligoadenylate (2-5A), the product of dsRNA-activated oligoadenylate synthetases (OASes), binds to ankyrin repeats near the amino terminus of RNase L, initiating a series of conformational changes that result in the activation of the endoribonuclease. A phylogenetically conserved RNA structure within group C enteroviruses inhibits the endoribonuclease activity of RNase L. In this study we report the mechanism by which group C enterovirus RNA inhibits RNase L. Viral RNA did not affect 2-5A binding to RNase L. Rather, the viral RNA inhibited the endoribonuclease domain. We used purified RNase L, purified 2-5A, and an RNA substrate with a 5' fluorophore and 3' quencher in FRET assays to measure inhibition of RNase L activity by the viral RNA. The group C enterovirus RNA was a competitive inhibitor of the endoribonuclease with a K(i) of 34 nM. Consistent with the kinetic profile of a competitive inhibitor, the viral RNA inhibited the constitutively active endoribonuclease domain of RNase L. We call this viral RNA the RNase L competitive inhibitor RNA (RNase L ciRNA).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18426919      PMCID: PMC2390801          DOI: 10.1261/rna.958908

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  44 in total

1.  Selective RNA cleavage by isolated RNase L activated with 2-5A antisense chimeric oligonucleotides.

Authors:  R H Silverman; B Dong; R K Maitra; M R Player; P F Torrence
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

2.  Monitoring activation of ribonuclease L by 2',5'-oligoadenylates using purified recombinant enzyme and intact malignant glioma cells.

Authors:  L Rusch; B Dong; R H Silverman
Journal:  Methods Enzymol       Date:  2001       Impact factor: 1.600

3.  Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p.

Authors:  B Dong; M Niwa; P Walter; R H Silverman
Journal:  RNA       Date:  2001-03       Impact factor: 4.942

Review 4.  Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures.

Authors:  S Goodbourn; L Didcock; R E Randall
Journal:  J Gen Virol       Date:  2000-10       Impact factor: 3.891

5.  Crystal structure of the 2'-specific and double-stranded RNA-activated interferon-induced antiviral protein 2'-5'-oligoadenylate synthetase.

Authors:  Rune Hartmann; Just Justesen; Saumendra N Sarkar; Ganes C Sen; Vivien C Yee
Journal:  Mol Cell       Date:  2003-11       Impact factor: 17.970

6.  Mfold web server for nucleic acid folding and hybridization prediction.

Authors:  Michael Zuker
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

Review 7.  Identification and characterization of viral antagonists of type I interferon in negative-strand RNA viruses.

Authors:  A García-Sastre
Journal:  Curr Top Microbiol Immunol       Date:  2004       Impact factor: 4.291

Review 8.  Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response.

Authors:  Robert H Silverman
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

Review 9.  The 2-5A/RNase L pathway and inhibition by RNase L inhibitor (RLI).

Authors:  C Bisbal; T Salehzada; M Silhol; C Martinand; F Le Roy; B Lebleu
Journal:  Methods Mol Biol       Date:  2001

10.  A specific substrate-inhibitor, a 2'-deoxy-2'-fluorouridine-containing oligoribonucleotide, against human RNase L.

Authors:  Yoshihito Ueno; Yuuki Yamada; Masayuki Nakanishi; Yukio Kitade
Journal:  Bioorg Med Chem       Date:  2003-11-17       Impact factor: 3.641

View more
  36 in total

1.  Structural architecture of an RNA that competitively inhibits RNase L.

Authors:  Amanda Y Keel; Babal Kant Jha; Jeffrey S Kieft
Journal:  RNA       Date:  2011-11-23       Impact factor: 4.942

2.  Sustained cytoplasmic delivery and anti-viral effect of PLGA nanoparticles carrying a nucleic acid-hydrolyzing monoclonal antibody.

Authors:  Yoon Ki Joung; Sejin Son; Ji Young Jang; Myung Hee Kwon; Ki Dong Park
Journal:  Pharm Res       Date:  2011-12-03       Impact factor: 4.200

Review 3.  Inhibition and avoidance of mRNA degradation by RNA viruses.

Authors:  Stephanie L Moon; Michael D Barnhart; Jeffrey Wilusz
Journal:  Curr Opin Microbiol       Date:  2012-05-23       Impact factor: 7.934

Review 4.  New insights into the role of RNase L in innate immunity.

Authors:  Arindam Chakrabarti; Babal Kant Jha; Robert H Silverman
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

5.  Kaposi's sarcoma-associated herpesvirus noncoding polyadenylated nuclear RNA interacts with virus- and host cell-encoded proteins and suppresses expression of genes involved in immune modulation.

Authors:  Cyprian C Rossetto; Gregory S Pari
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

6.  Global RNA structure analysis of poliovirus identifies a conserved RNA structure involved in viral replication and infectivity.

Authors:  Cecily P Burrill; Oscar Westesson; Michael B Schulte; Vanessa R Strings; Mark Segal; Raul Andino
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

7.  A noncoding RNA produced by arthropod-borne flaviviruses inhibits the cellular exoribonuclease XRN1 and alters host mRNA stability.

Authors:  Stephanie L Moon; John R Anderson; Yutaro Kumagai; Carol J Wilusz; Shizuo Akira; Alexander A Khromykh; Jeffrey Wilusz
Journal:  RNA       Date:  2012-09-24       Impact factor: 4.942

8.  West Nile virus noncoding subgenomic RNA contributes to viral evasion of the type I interferon-mediated antiviral response.

Authors:  Andrea Schuessler; Anneke Funk; Helen M Lazear; Daphne A Cooper; Shessy Torres; Stephane Daffis; Babal Kant Jha; Yutaro Kumagai; Osamu Takeuchi; Paul Hertzog; Robert Silverman; Shizuo Akira; David J Barton; Michael S Diamond; Alexander A Khromykh
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

9.  Viral manipulation of host mRNA decay.

Authors:  Liang Guo; Irina Vlasova-St Louis; Paul R Bohjanen
Journal:  Future Virol       Date:  2018-02-23       Impact factor: 1.831

10.  Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies.

Authors:  Woo-Ram Lee; Ji-Young Jang; Jeong-Sun Kim; Myung-Hee Kwon; Yong-Sung Kim
Journal:  Nucleic Acids Res       Date:  2009-12-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.